[go: up one dir, main page]

PL1789434T3 - Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek - Google Patents

Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek

Info

Publication number
PL1789434T3
PL1789434T3 PL05775826T PL05775826T PL1789434T3 PL 1789434 T3 PL1789434 T3 PL 1789434T3 PL 05775826 T PL05775826 T PL 05775826T PL 05775826 T PL05775826 T PL 05775826T PL 1789434 T3 PL1789434 T3 PL 1789434T3
Authority
PL
Poland
Prior art keywords
aminomethane
hydroxymethyl
polypeptides
peptides
stabilization
Prior art date
Application number
PL05775826T
Other languages
English (en)
Inventor
Ingun Christiansen
Arne Staby
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL1789434T3 publication Critical patent/PL1789434T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05775826T 2004-08-31 2005-08-26 Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek PL1789434T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200401310 2004-08-31
EP05775826.0A EP1789434B1 (en) 2004-08-31 2005-08-26 Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
PCT/EP2005/054209 WO2006024631A2 (en) 2004-08-31 2005-08-26 Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins

Publications (1)

Publication Number Publication Date
PL1789434T3 true PL1789434T3 (pl) 2014-07-31

Family

ID=35311457

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05775826T PL1789434T3 (pl) 2004-08-31 2005-08-26 Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek

Country Status (6)

Country Link
US (1) US8710181B2 (pl)
EP (1) EP1789434B1 (pl)
JP (1) JP4965446B2 (pl)
ES (1) ES2442223T3 (pl)
PL (1) PL1789434T3 (pl)
WO (1) WO2006024631A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US8907059B2 (en) * 2008-11-14 2014-12-09 Bio-Rad Laboratories, Inc. Phosphopeptide enrichment of compositions by fractionation on ceramic hydroxyapatite
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
WO2013158276A1 (en) * 2012-04-20 2013-10-24 Children's Hospital Medical Center Antibody binding microbial heparin binding motif to retard or prevent microbial biofilm formation on implanted medical devices
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
CN103321100B (zh) * 2013-06-26 2015-07-22 广东工业大学 一种纸张脱酸剂及其使用方法
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽-4(exendin-4)胜肽類似物
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/gip受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー/エス Glp-1アゴニスト及び腸溶コーティングを含む錠剤
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
CN110526982B (zh) * 2018-05-23 2023-08-01 信立泰(成都)生物技术有限公司 一种人胰高血糖素样肽-1类似物融合蛋白的纯化方法
CN109851667A (zh) * 2018-12-29 2019-06-07 江苏万邦医药科技有限公司 一种德谷胰岛素前体的纯化方法
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition
TW202327643A (zh) * 2021-09-10 2023-07-16 丹麥商西蘭製藥公司 包含類升糖素肽2(glp-2)類似物之組合物之調配方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468346A (en) * 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
EP0368864B1 (en) * 1987-05-14 1993-11-03 Commonwealth Scientific And Industrial Research Organisation Whey protein fractions
JPH03505401A (ja) 1988-06-27 1991-11-28 ジェネックス・コーポレーション 組換えタンパク質の培養培地への熱放出
DE69013471T2 (de) 1989-12-05 1995-03-30 Merck & Co Inc Methode zur Stabilisierung von rekombinanten Hepatitis-B-Virus-Oberflächenproteinen aus Hefe.
DE4002066A1 (de) 1990-01-25 1991-08-01 Basf Ag Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
SE9101381D0 (sv) 1991-05-07 1991-05-07 Tomas Moks Peptide hormone solution
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
SG45449A1 (en) 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
GB9320782D0 (en) * 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
PT729362E (pt) 1993-11-19 2000-06-30 Searle & Co Composicao transdermica de n-¬n-¬5-¬4-(aminoiminometil)fenil|-1oxopentil|-l-alfa-aspartil|-l-fenillalanina ou esteres e seus sais farmaceuticamente aceitaveis
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1995022560A1 (en) 1994-02-22 1995-08-24 The Syntex-Synergen Neuroscience Joint Venture Pharmaceutical formulations of cntf
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
AU710419B2 (en) 1994-08-05 1999-09-23 Bausch & Lomb Incorporated Device for inserting a flexible intraocular lens
CA2157219C (en) 1994-08-31 2010-10-05 Munehiro Noda Process for purifying recombinant human serum albumin
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69529998D1 (de) 1994-12-23 2003-04-24 Novo Nordisk As Glp-1 zusammensetzungen mit verlängerter wirkdauer
US5834428A (en) * 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
DK0828753T3 (da) 1995-06-02 2003-06-30 Novozymes As A1/Fe-behandling af en proteinopløsning efterfulgt af membranopkoncentrering
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
JPH10101696A (ja) 1996-08-08 1998-04-21 Shinotesuto:Kk 形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質
US6384016B1 (en) * 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP0998942A4 (en) 1997-01-20 2006-08-16 Japan Energy Corp METHOD FOR STABILIZING PEPTIDES AND FREEZERED MEDICINAL COMPOSITIONS THEREOF
CA2236519C (en) * 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
CA2306024C (en) 1997-10-01 2011-04-26 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
WO1999021889A1 (en) * 1997-10-24 1999-05-06 Genentech, Inc. Purification of molecules
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
ATE466027T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
DE69942307D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
AU2610799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 per cent, forming partially structured micellar-like aggregates
EP1113799A4 (en) 1998-09-17 2004-06-09 Lilly Co Eli PROTEIN-BASED PREPARATION
ATE307603T1 (de) 1998-12-22 2005-11-15 Lilly Co Eli Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
AU777564B2 (en) 1999-01-14 2004-10-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof
US6444788B1 (en) * 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
HUP0200297A3 (en) 1999-03-17 2002-09-30 Novo Nordisk As Method for acylating peptides and the glutaminic acid derivatives as acylating agents
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
PT1242121E (pt) 1999-12-16 2005-05-31 Lilly Co Eli Composicoes polipeptidicas com estabilidade melhorada
US7022674B2 (en) * 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
WO2001052937A1 (en) * 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
WO2001055213A2 (en) * 2000-01-27 2001-08-02 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (glp-1) compounds
EP1396499A3 (en) 2000-01-27 2004-12-29 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
WO2001077141A1 (en) 2000-04-06 2001-10-18 Novo Nordisk A/S Shock heat treatment of polypeptides
BR0111562A (pt) * 2000-06-16 2003-04-15 Lilly Co Eli Análogos de peptìdeo 1 semelhantes ao glucagon
JP4798833B2 (ja) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 加熱処理工程を含むヒト血清アルブミンの製造方法
WO2002048192A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Amidated glucagon-like peptide-1
US20020151467A1 (en) * 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
GB2371227A (en) 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
WO2002066511A2 (en) * 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
CN1335182A (zh) 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
CN1635900A (zh) 2001-08-28 2005-07-06 伊莱利利公司 Glp-1和基础胰岛素的预混合物
US7179788B2 (en) 2001-10-19 2007-02-20 Eli Lilly And Company Biphasic mixtures of GLP-1 and insulin
JP2005526084A (ja) * 2002-03-15 2005-09-02 ナットイムネ・アクティーゼルスカブ マンノース結合レクチンを含む医薬組成物
JP2005535569A (ja) * 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー/エス Glp−1アゴニスト及び心臓血管合併症
AU2003266216A1 (en) 2002-09-25 2004-04-19 Novo Nordisk A/S Purification process comprising microfiltration at elevated temperatures
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
ES2425221T3 (es) 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
MXPA05013048A (es) 2003-06-03 2006-03-02 Novo Nordisk As Composiciones peptodicas farmaceuticas estabilizadas.
PL1633391T3 (pl) * 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
CN1812808B (zh) * 2003-06-03 2012-07-04 诺沃挪第克公司 稳定化的药物肽组合物
EP1684793B1 (en) 2003-11-13 2011-09-21 Novo Nordisk A/S Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
US20060287221A1 (en) * 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION

Also Published As

Publication number Publication date
EP1789434B1 (en) 2013-11-20
WO2006024631A3 (en) 2006-06-15
US8710181B2 (en) 2014-04-29
JP2008511583A (ja) 2008-04-17
US20080171848A1 (en) 2008-07-17
WO2006024631A2 (en) 2006-03-09
JP4965446B2 (ja) 2012-07-04
EP1789434A2 (en) 2007-05-30
ES2442223T3 (es) 2014-02-10

Similar Documents

Publication Publication Date Title
PL1789434T3 (pl) Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
IL183405A0 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
DK1680443T3 (da) Stabiliserede alfa-helix-peptider og anvendelser heraf
WO2006017538A3 (en) Hk1-binding proteins
IL171109A (en) Glycopagilization methods and proteins / peptides produced by these methods
EP1732581A4 (en) POLYPEPTIDE TRANSDUCTION AND FUSOGENIC PEPTIDES
WO2004087874A3 (en) Novel nucleic acids and polypeptides
GB0426154D0 (en) IGF-1 novel peptides
EP1735335A4 (en) Cell-killing peptide
IS8308A (is) Amínósýrur með sækni fyrir a2o prótíninu
EP1614695A4 (en) POLYPEPTIDE
ZA200508028B (en) Glycopegylation methods and proteins/peptides produced by the methods
FI20040655L (fi) Proteiini- ja peptidistabilointi
SI1824876T1 (sl) Motivi polipeptidne družine trebušne slinavke, polipeptidi in postopki, ki jih vsebujejo
DE602005014597D1 (de) Peptide zur Unterscheidung von Prionen
GB0521490D0 (en) RFamide-related peptide precursor proteins and RFamide peptides
AU2003280316A8 (en) Zymogen-like protein c polypeptides
GB2441941B (en) An isolated recombinant vaccinia virus complement control protein (HRVCP) polypeptide
WO2006020541A3 (en) Methods for synthesizing polypeptides
GB2415195B (en) Peptides of IRF-1
ZA200700130B (en) Glycopegylation methods and proteins/peptides produced by the methods
SI1615945T1 (sl) Glikopegilacijski postopki in proteini peptidi izdelani s postopki
GB0217894D0 (en) Homing peptides
AU2004901587A0 (en) Site-selective derivatisation of peptides and proteins
AU2005901685A0 (en) Site-selective derivatisation of peptides and proteins